Unlock instant, AI-driven research and patent intelligence for your innovation.

Rivaroxaban synthesis method

A technology of rivaroxaban and compounds, applied in the production of bulk chemicals, organic chemistry, etc., can solve the problems of increasing the cost of chromatographic columns

Active Publication Date: 2015-11-25
新方正控股发展有限责任公司 +2
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] The above route also has the problem of requiring a chromatographic column for chiral separation resulting in increased costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rivaroxaban synthesis method
  • Rivaroxaban synthesis method
  • Rivaroxaban synthesis method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Embodiment 1: Preparation of 4-(4-carbaaminophenyl)-3-morpholinone (formula III):

[0086]

[0087] Add 192.2g (1.0mol) of 4-(4-aminophenyl)-3-morpholinone (formula II) into the reaction flask, stir and dissolve with 700ml dichloromethane, cool to 25°C, add dropwise 45.0g (1.5 mol) formaldehyde, the temperature of the dropping process is controlled at 20°C to 30°C, the dropwise addition is completed, and the reaction is stirred for 5 hours, controlled by TLC (dichloromethane:methanol:triethylamine=20:1:0.5, volume ratio), the reaction Completely, stop stirring, distill dichloromethane under reduced pressure (-0.1MPa~-0.09MPa), add 600ml ethyl acetate to raise temperature and reflux, cool down naturally under stirring, drop to 10°C to 15°C for 8 hours, filter, reduce After drying under pressure, 185.4 g of off-white intermediate III was obtained, with a molar yield of 90.8% and an HPLC purity of 98.8%.

[0088] The detection data of the title product obtained by NMR ...

Embodiment 2

[0089] Embodiment 2: Preparation of 4-(4-carbaaminophenyl)-3-morpholinone (formula III):

[0090] Add 192.2g (1.0mol) of 4-(4-aminophenyl)-3-morpholinone into the reaction flask, stir and dissolve with 700ml of dichloromethane, cool to 25°C, add 75.0g (2.5mol) of formaldehyde dropwise, The temperature of the dropping process was controlled at 20°C to 30°C. After the dropwise addition was completed, the reaction was stirred for 2 hours. TLC was controlled (dichloromethane:methanol:triethylamine=20:1:0.5, volume ratio), the reaction was complete, and the stirring was stopped. , dichloromethane was evaporated under reduced pressure (-0.1MPa~-0.09MPa), 600ml of ethyl acetate was added to raise the temperature and reflux, the temperature was naturally lowered under stirring, and the crystallization was carried out at 10°C to 15°C for 8 hours, filtered, and dried under reduced pressure. 188.1 g of off-white intermediate III was obtained, the molar yield was 92.1%, and the HPLC purit...

Embodiment 3

[0092] Example 3: Preparation of (S)-1-chloro-2-[2-(1,3-dioxoisoindol)yl]ethyl chloroformate (Formula V):

[0093]

[0094] In this embodiment, X in the above is Cl.

[0095] Add 270.7g (1.2mol) of (S)-2-(2-chloro-2-hydroxyethyl)isoindole-1,3-dione (formula IV), 158.2g (2.0mol) Pyridine and 1000ml tetrahydrofuran, stir evenly, cool down to 10°C to 20°C, add 267.1g (0.9mol) triphosgene, keep stirring and react for 2 hours, then add 89.0g (0.3mol) triphosgene, continue stirring for 3 hours, Under the control of HPLC, the raw materials basically disappeared, and the reaction was stopped. The tetrahydrofuran was evaporated under reduced pressure (-0.1MPa~-0.09MPa), and 800ml of dichloromethane was added to the residual oil and stirred to dissolve. Wash with purified water in sequence until the pH value of the aqueous phase is about 6, and distill the organic layer obtained by liquid separation under reduced pressure (-0.1MPa~-0.09MPa) to remove dichloromethane to obtain 294.6g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a rivaroxaban synthesis method, wherein 4-(4-methylamino alkenyl phenyl)-3-morpholinone and (S)-{1-(chloroformate)-2-[2-(1,3-dioxo-isoindol)yl]ethyl}halogenation salt are subjected to a ring-closing reaction to prepare a key intermediate (S)-2-{[2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidine-5-yl]methyl}isoindole-1,3-dione, the amino protection group is removed from the key intermediate to prepare 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholine-3-one hydrochloride, and the 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholine-3-one hydrochloride and 2-chloroformyl-5-chlorothiophene are further subjected to a reaction to obtain the rivaroxaban. The method of the present invention has characteristics of mild preparation conditions, simple process, low cost and high yield, and is suitable for industrial production.

Description

technical field [0001] The invention belongs to the technical field of chemical synthesis, and specifically relates to a key intermediate (S)-2-{[2-oxo-3-(4-(3-oxomorpholine)phenyl) by synthesizing rivaroxaban Oxazolidin-5-yl]methyl}isoindole-1,3-dione, and further a method for preparing rivaroxaban. Background technique [0002] Thrombosis, which is the formation of localized blood clots. Among them, arterial thrombosis can lead to myocardial infarction, stroke, acute coronary syndrome and peripheral arterial disease. Arterial and venous thrombosis is the leading cause of cardiovascular disease morbidity and death, and it is also one of the leading causes of death in cancer patients. The traditional anticoagulant drugs heparin and warfarin are routine methods for the treatment and prevention of arterial and venous thrombosis. Large-scale clinical trials and clinical applications have established their status as traditional anticoagulant drugs. However, heparin is adminis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D413/14C07D265/32C07D209/48
CPCY02P20/55C07D413/14C07D209/48C07D265/32
Inventor 徐虹李林风张铮王威任娟
Owner 新方正控股发展有限责任公司